• Posted in:

    IMI 2. Call 13 (Pre-anuncio)

    To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes draft topic texts on this page several weeks before the official Call launch. To ensure you get the latest information on forthcoming Calls, sign up to our newsletter, follow us on Twitter, or join our LinkedIn group. Draft topic […]

    Leer más

  • Posted in:

    IMI 2. Future Calls modificadas (Pre-anuncio)

    Las futuras convocatorias de IMI serán ampliadas con los siguientes topics provisionale: IMI 2. Future Calls Future Topics | IMI – Innovative Medicines Initiative European Health Data Network (EHDN)  Future Topics | IMI – Innovative Medicines Initiative  – New in May 2017 Analysing the infectious disease burden and the use of vaccines to improve healthy […]

    Leer más

  • Posted in:

    IMI 2. 10 Call (Pre-anuncio)

    The following topics are under consideration for inclusion in IMI2 – Call 10, which is scheduled for launch in autumn 2016. The topics will also be presented, along with IMI’s rules and procedures, at the IMI Stakeholder Forum on 28-29 September in Brussels, Belgium. The event will also feature opportunities to network with fellow participants […]

    Leer más

  • Posted in:

    IMI2 (Call 9). Preanuncio

    Se están considerando los siguientes topics para la 9ª convocatoria. Esta información es indicativa y puede sufrir cambios hasta su publicación definitiva. A European distributed data network (DDN) project to facilitate intra-EU access to, and analysis of, real world data to improve health outcomes for EU patients Note: topic forms part of the IMI Big Data for Better […]

    Leer más

  • Posted in:

    IMI 2. Iniciativa Medicamentos Innovadores

    Fecha inicio: 09.07.2015 Fecha límite: 13.10.2015 Importe: 47.4770.000 Topics: Topic 1: Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies Topic 2: Diabetic kidney disease biomarkers (DKD-BM) Topic 3: Inflammation and AD: modulating microglia function […]

    Leer más